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background:  Bivalirudin compared with platelet glycoprotein IIbIIIa inhibitors (GPI) was associated with reduced bleeding, increased stent 
thrombosis and improved survival in patients undergoing primary PCI (PPCI) in the HORIZONS AMI trial. These findings have not been externally 
corroborated.
Methods: Our study cohort comprised of patients undergoing PPCI across 47 hospitals in Michigan between 2010 and 2012. Patients receiving 
Bivalirudin +/- GPI were compared to those receiving heparin + GPI. Propensity score matching (PSM) on a 1:1 basis without replacement was 
utilized to account for confounding.
results: Of 10,985 admissions for PPCI included in the analysis, Bivalirudin was used in 2,603 (24%) and GPI in 8,382 (76%). In-hospital mortality was 
similar, both overall (4.9% Bival vs. 5.0% GPI, p = 0.8) and after PSM (4.8% vs. 4.7%, p =0.9). GPI use was associated with increased post PCI bleeding 
events (overall: 4.1% vs. 7.4%, p < .001; PSM: 4.0% vs. 6.9%, p <.001), no difference in transfusion rates (overall 5.8% vs 6.9%, p = .052, PSM 5.7% 
vs 6.3%, p = 0.37) and a reduction in early stent thrombosis (overall: 0.56% versus 1.11%, p =0.004; PSM: 0.63% vs. 1.11%, P=0.09) Among 2,658 
patients (median 1.2 years) for whom follow up data were available, no significant difference in mortality was observed (figure, p = .63).
conclusions: Bivalirudin and GPI anticoagulation strategies appear to be associated with similar early and late mortality in this large unselected 
cohort of patients undergoing primary PCI.
 
